Equity Overview
Price & Market Data
Price: $0.17
Daily Change: -$0.0098 / 5.76%
Daily Range: $0.169 - $0.208
Market Cap: $3,517,055
Daily Volume: 606,587
Performance Metrics
1 Week: -4.44%
1 Month: -32.74%
3 Months: -40.11%
6 Months: -44.05%
1 Year: -70.16%
YTD: -60.02%
Company Details
Employees: 12
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.